EP1191975A4 - Amelioration de l'immunite induite par les lymphocytes t - Google Patents

Amelioration de l'immunite induite par les lymphocytes t

Info

Publication number
EP1191975A4
EP1191975A4 EP00916705A EP00916705A EP1191975A4 EP 1191975 A4 EP1191975 A4 EP 1191975A4 EP 00916705 A EP00916705 A EP 00916705A EP 00916705 A EP00916705 A EP 00916705A EP 1191975 A4 EP1191975 A4 EP 1191975A4
Authority
EP
European Patent Office
Prior art keywords
improvement
cell mediated
mediated immunity
immunity
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00916705A
Other languages
German (de)
English (en)
Other versions
EP1191975A2 (fr
Inventor
Richard Lennox Boyd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Norwood Immunology Ltd
Original Assignee
Monash University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monash University filed Critical Monash University
Publication of EP1191975A2 publication Critical patent/EP1191975A2/fr
Publication of EP1191975A4 publication Critical patent/EP1191975A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP00916705A 1999-04-15 2000-04-17 Amelioration de l'immunite induite par les lymphocytes t Withdrawn EP1191975A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPP9778A AUPP977899A0 (en) 1999-04-15 1999-04-15 Improvement of t cell mediated immunity
AUPP977899 1999-04-15
PCT/AU2000/000329 WO2000062657A2 (fr) 1999-04-15 2000-04-17 Amelioration de l'immunite induite par les lymphocytes t

Publications (2)

Publication Number Publication Date
EP1191975A2 EP1191975A2 (fr) 2002-04-03
EP1191975A4 true EP1191975A4 (fr) 2005-05-25

Family

ID=3813977

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00916705A Withdrawn EP1191975A4 (fr) 1999-04-15 2000-04-17 Amelioration de l'immunite induite par les lymphocytes t

Country Status (11)

Country Link
EP (1) EP1191975A4 (fr)
JP (1) JP2002542174A (fr)
KR (1) KR20020007371A (fr)
CN (1) CN100376288C (fr)
AU (2) AUPP977899A0 (fr)
BR (1) BR0009712A (fr)
CA (1) CA2370296A1 (fr)
HK (1) HK1046249A1 (fr)
NZ (1) NZ514975A (fr)
WO (1) WO2000062657A2 (fr)
ZA (1) ZA200108451B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040258672A1 (en) * 1999-04-15 2004-12-23 Monash University Graft acceptance through manipulation of thymic regeneration
AUPR074500A0 (en) * 2000-10-13 2000-11-09 Monash University Treatment of t cell disorders
US20020086000A1 (en) * 1999-04-15 2002-07-04 Richard Boyd Stimulation of thymus for vaccination development
US20020071829A1 (en) * 1999-04-15 2002-06-13 Richard Boyd Normalization of defective T cell responsiveness through manipulation of thymic regeneration
AU2002225245C1 (en) * 2000-10-13 2008-07-17 Norwood Immunology Ltd Improvement of graft acceptance through manipulation of thymic regeneration
IL155412A0 (en) * 2000-10-13 2003-11-23 Univ Monash Diagnostic indicator of thymic function
AU2002216320C1 (en) * 2000-10-13 2008-04-03 Norwood Immunology Ltd Hematopoietic stem cell gene therapy
WO2002030259A2 (fr) * 2000-10-13 2002-04-18 Monash University Prevention de maladies par reactivation du thymus
AU2002216323C1 (en) * 2000-10-13 2008-05-29 Norwood Immunology Ltd Disease prevention by reactivation of the thymus
WO2002030351A2 (fr) * 2000-10-13 2002-04-18 Monash University Ameliorations de l'acceptation d'un greffon par manipulation de la regeneration thymique
AU2001295270B2 (en) * 2000-10-13 2007-08-09 Norwood Immunology Ltd Treatment of T cell disorders
EP1357978A4 (fr) * 2000-10-13 2004-05-19 Richard Boyd Therapie genique aux cellules souches hematopoietiques
IL147138A0 (en) * 2001-12-17 2002-08-14 Yeda Res & Dev Methods of and pharmaceutical compositions for modulating cell adhesion, migration and extravasation
WO2004103271A2 (fr) * 2003-04-18 2004-12-02 Norwood Immunology, Ltd. Prevention de maladies et vaccination avant reactivation thymique
CA2698985A1 (fr) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Utilisation d'un peptide comme agent therapeutique
US9910039B2 (en) * 2011-07-01 2018-03-06 Beckman Coulter, Inc. Regulatory T cells and methods of identifying, obtaining and using to treat immuno-based disorders
CN103235135B (zh) * 2013-04-26 2015-02-04 史其新 一种用于表征外周调节性t细胞抑制活性的特征细胞群的检测方法及其应用
CA3043594A1 (fr) * 2016-11-11 2018-05-17 Longeveron Llc Procedes d'utilisation de cellules souches mesenchymateuses humaines pour induire une immunite cellulaire et humorale
RU2020124312A (ru) * 2018-02-23 2022-03-23 Дюк Юниверсити Энд Медикал Сентр Трансплантация культуры ткани тимуса способствует донор-специфической толерантности к аллогенным трансплантатам паренхиматозных органов
US11819520B2 (en) 2018-02-23 2023-11-21 Duke University Cultured thymus tissue transplantation promotes donor-specific tolerance to allogeneic solid organ transplants

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988001176A1 (fr) * 1986-08-18 1988-02-25 Bunge (Australia) Pty. Ltd. Regulation de la reproduction animale
WO1992019746A1 (fr) * 1991-04-29 1992-11-12 Csl Limited Vaccin de castration immunologique recombine et polypeptides destines a cet usage

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988001176A1 (fr) * 1986-08-18 1988-02-25 Bunge (Australia) Pty. Ltd. Regulation de la reproduction animale
WO1992019746A1 (fr) * 1991-04-29 1992-11-12 Csl Limited Vaccin de castration immunologique recombine et polypeptides destines a cet usage

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LANDSTRÖM M ET AL: "Apoptosis in rat prostatic adenocarcinoma is associated with rapid infiltration of cytotoxic T-cells and activated macrophages.", INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER. 2 MAY 1997, vol. 71, no. 3, 2 May 1997 (1997-05-02), pages 451 - 455, XP002322556, ISSN: 0020-7136 *
PLOSKER G L ET AL: "Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders.", DRUGS. DEC 1994, vol. 48, no. 6, December 1994 (1994-12-01), pages 930 - 967, XP001202673, ISSN: 0012-6667 *

Also Published As

Publication number Publication date
AU3797700A (en) 2000-11-02
AU779067B2 (en) 2005-01-06
ZA200108451B (en) 2003-01-15
CN1364093A (zh) 2002-08-14
NZ514975A (en) 2004-03-26
AUPP977899A0 (en) 1999-05-13
JP2002542174A (ja) 2002-12-10
EP1191975A2 (fr) 2002-04-03
BR0009712A (pt) 2002-04-30
HK1046249A1 (zh) 2003-01-03
CA2370296A1 (fr) 2000-10-26
WO2000062657A2 (fr) 2000-10-26
CN100376288C (zh) 2008-03-26
WO2000062657A3 (fr) 2001-01-11
KR20020007371A (ko) 2002-01-26

Similar Documents

Publication Publication Date Title
HK1046249A1 (zh) 改良t細胞的免疫反應
HK1034818A1 (en) Inverter
DE50008784D1 (en) Glas/kunststoff-compounds
HUP0201133A2 (en) Electrode structure
GB9919462D0 (en) Hydrocyclone
EP1218407A4 (fr) Utilisation de la kappa-conotoxine pviia
IL145990A0 (en) Novel 8a-and 9a-15-membered lactams
GB2351739B (en) Electrode
GB2356365B (en) Centrifuge
EP1229795A4 (fr) Chimiokine beta 13 humaine
GB2355942B (en) Separator
GB9917205D0 (en) Separator
GB9913884D0 (en) Separator
TW412052U (en) Structure of switch
TW393983U (en) Structural improvement of stemware
TW468411U (en) Structure of cardcase
TW394123U (en) Structure of emery-roller
GB9902952D0 (en) Pepin
TW399438U (en) Improved structure of bedhead
TW410808U (en) Improved structure of garbage can
TW389046U (en) Structure of hairgrip combinations
GB9927799D0 (en) Electrodes
GB9925746D0 (en) Separator
PL337258A1 (en) Separator
GB9903100D0 (en) Centrifuge

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011105

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050412

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NORWOOD IMMUNOLOGY, LTD.

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1046249

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20091103